Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 3/20 | 0.38 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807163 | 0.97 | MPO (0.38) | MPOITGAVITGB6FGFR4CTSK | |
| SCHEMBL24908851 | 0.97 | MPO (0.39) | MPOITGAVITGB6FGFR4CTSK | |
| SCHEMBL21328581 | 0.91 | MPO (0.39) | MPOITGAVITGB6FGFR4GPR119 | |
| SCHEMBL20481168 | 0.90 | MPO (0.38) | MPOITGAVITGB6FGFR4GPR119 | |
| SCHEMBL19953719 | 0.90 | MPO (0.39) | MPOITGAVITGB6FGFR4GPR119 | |
| SCHEMBL22223394 | 0.89 | ITGAV (0.40) | MPOITGAVITGB6GPR119ITGB3 | |
| SCHEMBL30474548 | 0.89 | ITGAV (0.40) | MPOITGAVITGB6GPR119ITGB3 | |
| SCHEMBL1820889 | 0.89 | GPR119 (0.38) | MPOITGAVITGB6CTSKMEN1 | |
| SCHEMBL17970755 | 0.89 | MPO (0.39) | MPOITGAVITGB6FGFR4GPR119 | |
| SCHEMBL16607380 | 0.89 | ITGAV (0.40) | MPOITGAVITGB6GPR119ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022008918-A1 | AZETIDINE DERIVATIVES FOR THE TREATMENT OF INTEGRIN ASSOCIATED DISEASES | UNIVERSITY OF NOTTINGHAM (GB) | 2022-01-13 | — | — | WO | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| EP-2493888-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011059839-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MPO 1747/4885ITGAV 4645/4885ITGB6 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.